Legend Biotech (LEGN) EBT (2019 - 2026)

Legend Biotech (LEGN) has 8 years of EBT data on file, last reported at -$53.8 million in Q1 2026.

• Quarterly EBT rose 45.77% year-over-year to -$53.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$237.4 million (down 20.21% YoY) and the FY2025 annual result came in at -$282.6 million, down 78.71% from the prior year.
• EBT slipped to -$53.8 million in Q1 2026, from -$19.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $40.6 million in Q4 2024 to a low of -$198.8 million in Q2 2023.
• A 5-year average of -$85.9 million and a median of -$84.8 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT slumped 33858.75% — and 2024, when it surged 127.65%.
• Tracing LEGN's EBT over 5 years: stood at -$135.7 million in 2022, then dropped by 8.17% to -$146.8 million in 2023, then surged by 127.65% to $40.6 million in 2024, then plunged by 148.52% to -$19.7 million in 2025, then tumbled by 173.1% to -$53.8 million in 2026.
• The last three EBT figures came in at -$53.8 million (Q1 2026), -$19.7 million (Q4 2025), and -$39.1 million (Q3 2025), per Business Quant data.